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Abstract
Background: Breast and ovarian cancers are predominant female cancers with increasing prevalence. The purpose
of this study was to estimate the population attributable risks (PARs) of breast and ovarian cancer occurrence based
on the relative risks (RRs) of modifiable reproductive factors and population-specific exposure prevalence.
Methods: The PAR was calculated by using the 1990 standardized prevalence rates, the 2010 national cancer incidence
with a 20 year lag period, the meta-analyzed RRs from studies conducted in the Korean population for breast cancer, and
the meta-analyzed RRs from a Korean epithelial ovarian cancer study and a prior meta-analysis, and ovarian cancer cohort
results up to 2012. For oral contraceptive and hormone replacement therapy use, we did not consider lag period.
Results: The summary PARs for modifiable reproductive factors were 16.7 % (95 % CI 15.8–17.6) for breast cancer (2404
cases) and 81.9 % (95 % CI 55.0–100.0) for ovarian cancer (1579 cases). The modifiable reproductive factors included
pregnancy/age at first birth (8.0 %), total period of breastfeeding (3.1 %), oral contraceptive use (5.3 %), and hormone
replacement therapy use (0.3 %) for breast cancer and included breastfeeding experience (2.9 %), pregnancy (1.2 %), tubal
ligation (24.5 %), and oral contraceptive use (53.3 %) for ovarian cancer.
Conclusions: Despite inherent uncertainties in the risk factors for breast and ovarian cancers, we suggest that appropriate
long-term control of modifiable reproductive factors could reduce breast and ovarian cancer incidences and their related
burdens by 16.7 % and 81.9 %, respectively.
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Background
Worldwide, breast cancer is the most common cancer
among females, and its incidence is increasing continu-
ously. Ovarian cancer is the third most common
gynecological cancer worldwide, next to cervix uteri and
corpus uteri cancers, and has the second highest mortal-
ity rate among gynecological cancers, following that for
cervix uteri cancer. Globally in 2008, breast and ovarian
cancers accounted for 26.6 % of all cancers among fe-
males [1]. The main risk factors for breast cancer are
reproductive factors such as age at menarche, number of
births (parity), age at first birth, lactation (breastfeeding),
and age at menopause [2]. Ovarian cancer is also influ-
enced by reproductive risk factors such as parity, breast-
feeding, and oral contraceptive (OC) use [3]. Each of
these reproductive factors is associated with changes in
circulating estrogen and progesterone levels and can be
controlled by exogenous hormone treatment, such as
OC use and menopausal hormone replacement therapy
(HRT). Epidemiological studies regarding hormonal fac-
tors support the hypothesis that female hormones, par-
ticularly exogenous hormones such as those used for OC
and HRT purposes, play an important role in the develop-
ment of breast and ovarian cancers in women [4, 5].
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In Korea, breast and ovarian cancers account for
14.3 % and 2.0 %, respectively, of all female cancers. In
Korea, breast cancer is the second most common cancer
following thyroid cancer, while ovarian cancer is ranked
as 10th most common among females [6]. Breast and
ovarian cancer incidences have been continuously in-
creasing over the past 20 years [7], and the average an-
nual percentage increases in breast and ovarian cancers
are 6.3 % and 1.6 %, respectively [6]. Increases in the
prevalence of breast and ovarian cancers have been
linked to rapid changes in reproductive factors, includ-
ing age at menarche, menopause, parity, and birth-
related characteristics (i.e., age at first birth, number of
births, and breastfeeding), as well as a rapidly ageing
population this country [8–10]. Particularly in Korea,
rapid development and economic growth since the 1950
Korean War have given rise to marked westernization,
leading to rapid changes in the reproductive risk factors
of cancers. In 2005, Korea implemented a nationwide
breast cancer screening program, which may be a con-
tributor to the increased prevalence of breast cancer
cases observed in this country.
The epidemiological patterns of breast and ovarian
cancers and their risk factors in Korean women may re-
quire the development of population-specific strategies for
cancer prevention. The determination of population at-
tributable risks (PARs), defined as the quantified contribu-
tion of each risk factor to a disease, can help policymakers
establish appropriate public health interventions [11].
The purpose of this study was to estimate the burden
of reproductive risk factors on the prevalence of breast
and ovarian cancer in Korea using Korean-specific risk
estimates. Since breast and ovarian cancers are major fe-
male cancers in the Korean population, such population-
specific prevalence and risk estimates should help in the
development of cancer control plans in Korea.
Methods
Selection of major risk factors
Prior studies focused on breast cancer risk factors in
Korea were based on a subset of data from the Seoul
Breast Cancer Study (SeBCS) [12–17], the largest com-
munity based case–control study between 1993 and
2007. The cases consisted of women diagnosed with his-
tologically confirmed breast cancer from three teaching
hospitals located in Seoul, accounting for about 15-18 %
of total breast cancer cases in Korea. The controls were
composed of non-cancer patients or health examinees
visiting the hospitals located in Seoul and near metro-
politan areas. After getting written informed consent, in-
formation on demographic characteristics, reproductive
factors, and lifestyle habits were collected by trained in-
terviewers using a structured questionnaire. The SeBCS
cases and controls were frequency matched by 5-year
age and three enrollment period categories (1993–1997,
1998–2000, and 2001–2007). As a result, 3789 case and
control sets were included in our analysis. Details of the
SeBCS are described elsewhere [18].
In our previous studies using subset of data from the
SeBCS, we have identified various risk factors of breast
cancer in Korea including early menarche, late meno-
pause, nulliparity, later first full-term pregnancy, family
history, postmenopausal obesity, breastfeeding, and OC
use [12–17]. For PAR calculations of potential risk fac-
tors, estimation of odds ratio (OR) for the full data set
from the SeBCS, not a subset, was needed to get a small
range for the 95 % confidence interval (CI). Next, we
performed a pooled data analysis and selected variables
according to the results from the multiple logistic re-
gression. As a result, age at menarche, age at meno-
pause, pregnancy age at first birth, total period of
breastfeeding, and OC use were selected as significant
reproductive factors. Of them, we chose pregnancy/age
at first birth, total period of breastfeeding, and OC use
as modifiable reproductive factors. “HRT use” was not a
significant variable according to our results. However,
we chose to include it since the IARC has reported that
HRT is a carcinogenic agent in humans [19]. Although
we selected risk factors for our new analysis, the selected
risk factors of breast cancer were the same as those pre-
viously recognized as risk factors in Korea.
For ovarian cancer, Holschneider et al. reviewed the
literature and proposed family history, genetic muta-
tions, nulliparity, late menopause, and early menarche as
risk factors for ovarian cancer. In addition, they sug-
gested that multiparity, oral contraceptive use, and hys-
terectomy or tubal ligation were protective factors [20].
We selected reproductive factors that have previously
been recognized as causal factors and the Korea Epithe-
lial Ovarian Cancer Study (Ko-Eve) data was applied to
estimate Korean OR values. The Ko-Eve study, started in
2009, is the only ongoing study in Korea. This commu-
nity based case–control study covers incident epithelial
ovarian cancers from six major centers and healthy con-
trols among health examinees from community hospitals
located in Seoul. Standardized questionnaires including
socio-demographics characteristics, past medical history,
family history, lifestyle habits, and reproductive factors
for women were administered by trained interviewers.
The details of the Ko-Eve are described elsewhere [21].
Initially, we analyzed the 231 cases registered from 2009
to 2011 and a group of 1:4 matched community controls
(N = 924). We estimated Korean OR values using our
ovarian cancer data from multiple logistic regression
models (backward) adjusted for age, education, and al-
leged risk factors reported in the literature. In this
process, family history of breast cancer, family history of
ovarian cancer, age at menarche, age at menopause,
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pregnancy, breastfeeding, tubal ligation, and OC use
were significant factors and were chosen. Afterwards, we
selected pregnancy, breastfeeding, and tubal ligation,
and OC use as modifiable factors.
Considering the effect of the population control pol-
icies through national birth control programs on the
rapid decline of the fertility rate in Korea [22], we in-
cluded ‘pregnancy/age at first birth’ for breast cancer
and ‘pregnancy’ for ovarian cancer as modifiable factors.
The variable pregnancy represented full-term pregnancy
excluding miscarriages and induced abortion.
Prevalence of exposure factors and cancer incidence
We applied the number of cancer incidents in the female
population aged 20 years and older in the year 2010
from the Korea Central Cancer, a nationwide cancer
registry in Korea [6]. Although several previous studies
regarding PARs have suggested approximately a 20-year
induction period, from exposure to risk to cancer devel-
opment [23–26], studies regarding PARs of reproductive
factors often suggested no lag time [27, 28]. In addition,
for OC, the increased breast cancer risk disappears ap-
proximately 10 years after cessation of use [29], and can-
cer risk decreases rapidly after cessation of HRT use.
Thus, no-lag time was considered and the prevalence in
2010 was estimated. We estimated the exposure preva-
lence of each selected modifiable reproductive risk factor
in Korean females by using the data from the Korea
National Health and Nutrition Examination Survey
(KNHANES), which was performed on a random repre-
sentative sample of the Korean population in 2005 [30].
Because the KNHANES did not include the history of
tubal ligation, we determined the prevalence of tubal
ligation based on the control subjects in the Ko-Eve
study [21]. We estimated prevalence by applying an age-
specific prevalence rate by 5-year age categories from
the KNHANES 2005 or the Ko-EVE studies to the fe-
male populations in 2010 and summed up the totals to
obtain standardized prevalence rates.
Meta-analysis for estimation of risk for breast and ovarian
cancers
To obtain the pooled relative risks (RRs) for the selected
risk factors, we conducted a meta-analysis of the results
of large-scale, case–control studies in Korea (SeBCS for
breast cancer and Ko-Eve for ovarian cancer) and the re-
sults from other previous studies. For breast cancer ana-
lysis, because the SeBCS included large numbers of
cases and matched controls, we restricted the data selec-
tion to studies conducted in Korea and did not restrict
the study design to reflect Korean risk estimates. For
ovarian cancer analysis, given that the Ko-Eve is the only
study conducted in Korea, and includes a limited num-
ber of cases, we included data from international studies
to perform a meta-analysis with Ko-EVE results to ob-
tain stable risk estimates. The priority for inclusion of
international data was meta-analysis or pooled analysis
data. In cases where studies were not available, we in-
cluded cohort study results. In cases where we could not
obtain RR or the raw data necessary for calculating a RR
estimate, the data were excluded from the meta-analysis.
Studies published in English or Korean before Decem-
ber 2012 were identified through PubMed (http://www.
ncbi.nlm.nih.gov/pubmed/), Embase (http://www.emba-
se.com/home), and KoreaMed (http://www.koreamed.
org/SearchBasic.php). The search keywords were cancer
(breast cancer, ovarian cancer) and each of the risk fac-
tors. For each article, we checked whether data resources
overlapped. When more than one study from the same
study population was available, the study with the most
complete data was used.
For breast cancer, in addition to the SeBCS, one study
[31] was included for meta-analysis of OC and HRT use,
and only the results from the SeBCS were applied for preg-
nancy/age at first birth and duration of breastfeeding be-
cause there were no prior study results in Korea. For
ovarian cancer, in addition to the Ko-Eve, 11 cohort studies
[32–42] were identified for pregnancy, but two studies [35,
38, 39] were excluded because of shared study populations
([39, 40] and [35, 41]) and one study of women with infer-
tility problems [38] was excluded. In order to obtain
pooled RRs, four cohort studies [36, 39, 42, 43] were in-
cluded for breastfeeding analysis (Additional file 1: Figure
S1) and meta-analysis studies were included for each tubal
ligation [44] and OC use [45], in addition to the Ko-Eve.
Meta-analysis estimates from both cohort studies and
case–control studies were applied to achieve our combined
results. In the meta-analysis, we did not access the incon-
sistency, publication bias, and other risk of bias. Stata ver-
sion 12.0 (StataCorp, College Station, TX, USA) was used
for the meta-analysis. The results from the included or
excluded studies are summarized in Additional file 2:
Table S1. The study design and the present study were
approved by the Seoul National University institutional
review board in compliance with the Helsinki Declar-
ation (IRB number: C-0909-048-295).
Statistical analysis
From the estimated prevalence of exposure in the popu-
lation (p) and the RRs for each particular risk factor, the
PAR for each risk can be calculated. The PAR was calcu-
lated by using the modified Levin’s formula for multiple
categories, as proposed by Hanley [46, 47].
PAF ¼
X
pi RRi−1ð Þ= 1þ
X
pi RRi−1ð Þ
 
PARs of breastfeeding duration for breast cancer, as
well as breastfeeding experience and tubal ligation for
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ovarian cancer were estimated using the prevalence of
pregnancy (97 %). PARs of HRT use for breast cancer
was estimated using the prevalence of menopause (32 %)
in women aged 20 years or over in 2010.
By using the obtained PARs, we calculated the propor-
tions and numbers of cases and deaths of breast and
ovarian cancer due to modifiable reproductive factors in
females 20 years of age and older.
Results
The RRs and prevalences for breast and ovarian cancer
applied in the current study along with the data sources
are summarized in Table 1. A later first pregnancy age
showed a higher risk for breast cancer, and those whose
total period of breastfeeding was ≤6 months showed an
increased breast cancer risk (RR = 1.28 [95 % CI 1.07–
1.53]) compared with females with a breastfeeding
period of ≥7 months. The use of OC was associated with
a 1.31-fold higher risk for breast cancer in the pooled
analysis (95 % CI 1.04–1.64); however, HRT use was not
significantly associated with breast cancer (RR = 1.16
[95 % CI 0.36–3.78]). Nulliparous women had a 1.42-
fold higher risk for ovarian cancer (95 % CI 1.31–1.54).
Women who did not have breastfeeding experience had
an increased risk of ovarian cancer (RR = 1.17 [95 % CI
1.02–1.33]). Female who did not undergo tubal ligation
had an increased risk of ovarian cancer (RR = 1.44 [95 %
CI 1.33–1.56]) and those who did not have experience to
take OC also had an increased risk (RR = 1.87 [95 % CI
0.89–3.94]).
The PARs and numbers of breast and ovarian cancer
incidences due to modifiable reproductive factors
among females aged 20 years and older for the year
2010 in Korea are presented in Table 2. Pregnancy/age
at first birth was the most important modifiable repro-
ductive factor for breast cancer (PAR = 8.0 %), followed
by OC use, total period of breastfeeding, and HRT
use, which were attributed to 5.3 %, 3.1 %, and
Table 1 Summary of relative risks and prevalence (%) of exposure to modifiable reproductive factors in Korean women and data
source
Risk factors Category Relative risk (95 % CI) Study design Source Prevalence (%)a Source
Breast cancer
Pregnancy/age at first birth Nulliparous 1.06 (0.82-1.36) Case–control
study
SeBCS 3 KNHANES, 2005
≤23 years 1.00 36
24 – 30 year 1.13 (0.98-1.32) 57
≥31 year 1.27 (0.98-1.66) 4
Total period of breast feeding Never 1.03 (0.87-1.21) Case–control
study
SeBCS 17 (18b) KNHANES, 2005
≤6 months 1.28 (1.07-1.53) 9 (10b)
≥7 months 1.00 70 (72b)
Oral contraceptive use Never 1.00 Meta-anlaysis SeBCS and [31] 82 KNHANES, 2005
Ever 1.31 (1.04-1.64) 18
Hormone replacement
therapy use
Never 1.00 30 (95c) KNHANES, 2005
Ever 1.16 (0.36-3.78) Meta-anlaysis SeBCS and [31] 2 (5c)
Ovarian cancer
Pregnancy Nulliparous 1.42 (1.31-1.54) Meta-anlaysis Ko-EVE, [32–34, 36, 37, 40–42] 3 KNHANES, 2005
Parous 1.00 97
Breast feeding experience Never 1.17 (1.02-1.33) Meta-anlaysis Ko-EVE, [36, 39, 42, 43] 17 (18b) KNHANES, 2005
Ever 1.00 79(82b)
Tubal ligation No 1.44 (1.33-1.56) Meta-anlaysis Ko-EVE and [44] 75 (77b) Ko-EVEd, 2009-2011
Yes 1.00 22 (23b)
Oral contraceptive use Never 1.87 (0.89-3.94) Meta-anlaysis Ko-EVE and [45] 82 KNHANES, 2005
Ever 1.00 18
aStandardized prevalence rates among women aged 20 or over by 1990 Korean population census data for pregnancy/age at first birth, total period of breast
feeding, pregnancy, breast feeding experience, and tubal ligation. Standardized prevalence rates among women aged 20 or over by 2010 Korean population
census data for oral contraceptive use and hormone replacement therapy
bPrevalence in parous women. In the Korean population, the prevalence of women with experience in breastfeeding was 97 %
cPrevalence in post-menopausal women. In the Korean population, the prevalence of post-menopausal women was 32 %
dUsed control population only
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0.3 %, respectively, of breast cancer incidences. The
PAR for the selected modifiable reproductive factors
was 16.7 % (95 % CI 15.8–17.6) for breast cancer, and
those factors were responsible for 2,404 (95 % CI
2,283–2,535) breast cancer cases in the year of 2010.
For ovarian cancer, OC use and tubal ligation were the
most important modifiable reproductive factors (PAR =
53.3 % [95 % CI 27.9-100.0] and PAR = 24.5 % [95 % CI
23.0–26.2], respectively), whereas breast feeding and
pregnancy were attributed to 2.9 % and 1.2 %, respect-
ively. The PAR for the selected modifiable reproductive
factors was 81.9 % (95 % CI 55.0–100.0) of ovarian can-
cer cases and they were responsible for 1579 (95 % CI
1059–1927) ovarian cancer incidences in the year of
2010 in Korea.
Discussion
In Korea in the year 2010, 16.7 % of breast cancer and
81.9 % of ovarian cancer cases in women were attribut-
able to modifiable reproductive factors. The modifiable
reproductive factors included pregnancy/age at first birth
(8.0 %), total period of breastfeeding (3.1 %), OC use
(5.3 %), and HRT use (0.3 %) for breast cancer and in-
cluded pregnancy (1.2 %), breastfeeding (2.9 %), tubal
ligation (24.5 %), and OC never use (53.3 %) for ovarian
cancer.
Several recent studies have reported PARs of repro-
ductive factors for breast cancer. In one study, a
combination of parity number and age at first birth
explained 17.9 % of breast cancers [48], a percentage
higher than that in our results for age at first birth
only (8.4 %). However, that study’s overall PAR of
breast cancer attributable to reproductive factors was
similar to ours. Barnes et al. included the most re-
ported risk factors for breast cancer including modifi-
able and non-modifiable factors in their PAR
calculation and showed that about 50 % of breast
cancers in post-menopausal women were attributed to
hormone and reproductive factors such as age at me-
narche (7.7 %), age at menopause (12.0 %), parity
(10.9 %), and HRT use (19.4 %) [49]. Parkin et al.
considered only breastfeeding and attributed it to
3.2 % of female breast cancers [50]. A study from
China showed that 6.7 % of breast cancers in women aged
15–49 years were attributed to reproductive factors, which
included parity, number of children, age at first birth, and
breastfeeding, and 0.7 % and 0.3 % were attributed to OC
use and HRT use, respectively [28].
Among the assessed modifiable reproductive factors,
large differences in PARs between studies were observed
in HRT use. In French women, HRT use was associated
with 12.7 % of breast cancer cases and 10.2 % of breast
cancer deaths [27], whereas HRT use was attributed to
19.4 % [49], 3.2 % [50], 0.3 % [28], 4.4 % [51], and 2.4 %
[52] of female breast cancer in Germany, the United
Kingdom, China, the United States, and Japan, respect-
ively. In the Korean population, the PAR of HRT was
very low (0.3 %), similar to that reported for China [28].
Table 2 The population attributable risks and estimated number of new cancer cases in Korean women caused by modifiable
reproductive factors in the year 2010
Cancer site Risk factors Population attributable risks % (95 % CI) Attributed N of casesc
Breast Pregnancy/age at first birth 8.0 (7.4-8.6) 1152 (1066–1246)
(Nullipara or age at first birth≥ 24 years)
Total period of breast feedinga 3.1 (3.1-3.2) 453 (441–464)
(Duration of breast feeding≤ 6 months)
Oral contraceptive use (Ever) 5.3 (5.1-5.5) 763 (732–795)
Hormone replacement therapy use (Ever)b 0.3 (0.2-0.3) 37 (29–44)
Total 16.7 (15.8-17.6) 2404 (2283–2535)
Ovary Pregnancy (Nulliparous) 1.2 (1.2-1.2) 24 (24–24)
Breast feeding experience (Never)a 2.9 (2.8-2.9) 55 (55–56)
Tubal ligation (No)a 24.5 (23.0-26.2) 473 (444–504)
Oral contraceptive use (Never) 53.3 (27.9-100.0d) 1027 (537–1927)
Total 81.9 (55.0-100.0 d) 1579 (1059–1927)
Attributed % of cases
% of breast cancer in women 16.7 (15.8-17.6)
% of ovary cancer in women 81.9 (55.0-100.0d)
aPAFs were considered only for parous females (97 % of total females)
bPAFs were considered only for post-menopausal females (32 % for total females)
cAttributable number of cases = population attributable risk X numbers of breast or ovarian cancer incidence in the year 2010 from National Cancer Registry
dThe population attributable risk exceed 100 (102.1) and truncated to 100
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The low level in Korea may be because HRT use is not
common in Korea (5 % in post-menopausal women) and
its RR is low.
Regarding the classification of risk factors, parity was
considered a non-modifiable factor in the work of
Barnes et al., but was assessed as a modifiable factor in
this study. Barnes et al. restricted their PAR calculation
to post-menopausal women, and parity-related factors
could thus be considered as non-modifiable [49]. In con-
trast, the present study included all women aged 20 or
older, and parity, pregnancy/age at first birth, and total
period of breastfeeding were thus classified as modifiable
factors. The International Agency for Research on Can-
cer and France working group estimated PAR changes
from 1980 to 2000 by assessing changes in reproductive
factors including parity (nulliparous vs. parous), mean
number of children, age at first birth, and breastfeeding
duration, and showed that changes in reproductive fac-
tors over those 20 years were associated with 6.7 % and
0.38 % of breast and ovarian cancers increases, respect-
ively [27]. Those results indicate that such factors can
produce temporal changes in cancer incidence. Korea
has an experience in decreasing fertility rate fast (from
6.0 births per woman in 1960 to 1.08 in 2005 and to
1.23 in 2010) through national birth control program as
part of a population control policies began in 1958.
Although the decreasing fertility rate is common
phenomenon worldwide, the speed of decrement is one
of the fast and now fertility rate in Korea is the lowest in
the world [22]. So, Korean government has changed
family planning policy to childbirth encouragement and
tries to increase the birth rate intensively with many
benefits to families. Considering that the PAR can help
policy makers establish appropriate public health inter-
ventions and efforts to control the birth rate in Korea
for about past 60 years, including pregnancy/age at first
birth as modifiable factors would helpful for policy-
makers not only in Korea but also other countries which
have family planning policy to support their recommen-
dation about childbirth. Thus, under this new policy, the
encouragement of childbirth, particularly at an early age,
might reduce breast and ovarian cancer incidences and
deaths.
With regard to the PAR in ovarian cancer, Granstrom
et al. reported that the PARs for family history, parity/
age at first birth, and residential area were 2.6 %, 22.3 %,
and 7.2 %, respectively [53]. Parazzini et al. included
more risk factors, and the PARs were 4 % for a family
history of breast and ovarian cancer, 8 % for age at
menopause, 5 % for parity, 12 % for OC use, 7 % for
high fat intake score, and 24 % for low green vegetable
intake [54]. Parkin et al. considered only HRT use as a
reproductive risk factor for ovarian cancer and attributed
0.7 % of the ovarian cancer incidence to HRT. The OC
use is a protective factor for ovarian cancer [55] and in
Korea the PAR of OC was higher than other studies be-
cause prevalence OC use was very low (18 %). As a
contraceptive method, tubal ligation was associated with
a lower risk of ovarian cancer and, during the era of en-
couraging birth control in Korea, the most common arti-
ficial sterilization method was tubal ligation. Therefore,
the PAR of tubal ligation for ovarian cancer was also
higher.
There are several study limitations to be considered.
Although the standardized population used in this
study was from 1990, prevalence of most reproductive
factors in 2005 was used because of the lack of repre-
sentative data for 1990. Considering the increased age
at first birth and the decreased fertility rate between
1990 and 2005, our results might underestimate the
PAR for reproductive factors in Korea. In addition, the
prevalence of tubal ligation showed limited represen-
tativeness because it was estimated by using control
subjects from a hospital-based case–control study
(Ko-Eve). Thus, we compared our estimates of the
prevalence of tubal ligation with results from the National
Survey on Fertility, Family Health & Welfare in Korea, a
nationwide representative survey for females of childbear-
ing age (15–44 years) [56], and the results were comparable
to ours (18.3 % vs. 23 %, respectively). Moreover, our esti-
mates of RRs were based on a limited number of studies,
which may have introduced uncertainty in the pooled RR
estimate and, hence, uncertainty in the calculated PARs. Al-
though several review articles and meta-analysis studies
have reported stable results for RR estimates of breast and
ovarian cancer risk factors, in this study, we used Korean-
specific results. We considered ethnicity- or country-
specific risk estimates, distributions, and their effects on
PAF estimates. In addition, while we did not consider the
quality of each study included in our RR estimation, Korean
studies included in the breast/ovarian cancer RR estimation
were community based case–control studies. For ovarian
cancer, we pooled results from previous international
studies with those from a Ko-Eve. Therefore, the RR
values might be less appropriate for the Korean fe-
male population. However, due to the lack of Korean
data and followed by instable results for ovarian can-
cer, pooled estimates with previous international stud-
ies would be unavoidable as Shin et al. did in the
previous study [26]. The cut-off points were arbitrary
and identified for convenience in our meta-analysis.
Despite these limitations, this study has several
strengths. First, we used nationwide cancer incidence
data that are representative of nearly the entire popu-
lation. Thus, we had access to precise numbers of
cancer cases for inclusion in our PAR estimation.
Second, the estimated prevalence of exposure to each
risk factor in 1990 was used in the consideration of a
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20-year lag period between exposure to a risk factor
and subsequent cancer development. Although we did
not measure the quality of each study, the studies in-
cluded in the meta-analysis for breast cancer were
conducted within the Korean population, thus provid-
ing Korean-specific results.
Conclusions
In summary, the results of this study represent a system-
atic assessment of breast and ovarian cancer risks and
the proportion of the risk associated with modifiable re-
productive factors. A total of 16.7 % of breast cancer
cases (2404 cases) and 81.9 % of ovarian cancer cases
(1579 cases) in Korea among female individuals 20 years
of age in 2010 were attributable to modifiable reproduct-
ive factors. Since breast and ovarian cancers are the
most prevalent female cancers, and are showing a trend
to higher prevalence, appropriate control of preventable
or modifiable risk factors is an important strategy for re-
duction of the female cancer burden in Korea. Combining
the current Korean family planning policy of childbirth
encouragement with cancer control strategies that affect
modifiable reproductive factors may help achieve reduc-
tions in breast and ovarian cancer incidences.
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